TY - JOUR T1 - Increasing P53 Protein Sensitizes Non-Small Cell Lung Cancer to Paclitaxel and Cisplatin <em>In Vitro</em> JF - Anticancer Research JO - Anticancer Res SP - 3557 LP - 3564 VL - 30 IS - 9 AU - VAMSI P. GUNTUR AU - J. CLIFFORD WALDREP AU - JENNIFER J. GUO AU - KIM SELTING AU - RAJIV DHAND Y1 - 2010/09/01 UR - http://ar.iiarjournals.org/content/30/9/3557.abstract N2 - Aim: To determine whether increasing p53 protein levels confers enhanced chemosensitivity in non-small cell lung cancer (NSCLC). Materials and Methods: Three NSCLC cell lines, with different endogenous p53 expression, were transfected with wild-type p53 (wt-p53) or CD-1 (truncated wt-p53) genes. Cells were subsequently treated with cisplatin (CDDP) or paclitaxel (PAX). Cell viability was measured using Alamar Blue Assay. Results: Cells transfected with CD-1 expressed 13-38% higher levels of p53 protein compared to cells transfected with the wt-p53 gene, despite their baseline endogenous levels. CD-1-transfected cells also had higher cell death when treated with CDDP (p&lt;0.05) or PAX, exhibiting 30-60% higher death rates than cells transfected with the wt-p53 gene and 130-160% higher than untransfected cells. A significant positive correlation between p53 protein concentration and cytotoxic response was demonstrated (R2 for CDDP=0.823; R2 for PAX=0.909; p&lt;0.001). Conclusion: Increasing intracellular p53 protein concentrations can augment the effect of CDDP and PAX in NSCLC, despite the baseline level of p53 protein expression. ER -